
Elicio Therapeutics fell 83.0% from $8.72 to $1.48, behind the S&P 500's +11.2%. Its worst day was Jun 15 (−72.5%), and its low came Nov 5 at $1.40.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.45 beat the $-0.46 estimate on $0.00 revenue.
+11.9% · S&P 500 −0.6%
EPS of $-0.65 missed the $-0.47 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
−9.1% · S&P 500 −0.2%
Elicio Therapeutics closed at its highest level of the year, 70.3% above where the year started.
+6.5% · S&P 500 +0.5%
Elicio Therapeutics shares fell 37.4%, while the S&P 500 fell 0.1%.
−37.4% · S&P 500 −0.1%
EPS of $-0.43 beat the $-0.54 estimate on $0.00 revenue.
−1.9% · S&P 500 −0.2%
EPS of $-0.30 beat the $-0.43 estimate on $0.00 revenue.
+7.9% · S&P 500 +0.3%
Where it ended: a close of $1.48 on Nov 16, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.34).
Nothing in the past 12 months.
All ELTX dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ELTX and SPY from Benzinga historical bars. Not investment advice.